Summary
Medtronic plc (MDT) reported its third-quarter fiscal year 2017 results, with net sales increasing by 5% to $7.3 billion compared to the prior year's third quarter. This growth was driven by solid performance across its key segments, particularly Cardiac and Vascular Group and Minimally Invasive Therapies Group, with contributions from new product launches and acquisitions. While overall net sales showed positive momentum, net income attributable to Medtronic declined by 25% to $821 million, primarily due to significant charges related to litigation and special contributions. The company also reported a decrease in diluted earnings per share to $0.59 from $0.77 in the prior year's comparable quarter. Despite the decline in net income, Medtronic demonstrated strong operational cash flow, generating $5.1 billion for the nine months ended January 27, 2017, and maintained a healthy free cash flow of $4.2 billion for the same period. The company continues to actively manage its capital structure, including share repurchases and debt management, while investing in research and development to drive future innovation. Investors should note the impact of certain litigation charges and special contributions on the quarter's profitability, which affected the GAAP net income, while the underlying business operations showed resilience.
Financial Highlights
52 data points| Revenue | $7.28B |
| Cost of Revenue | $2.27B |
| Gross Profit | $5.01B |
| SG&A Expenses | $2.39B |
| Operating Income | $1.15B |
| Interest Expense | $268.00M |
| Net Income | $821.00M |
| EPS (Basic) | $0.60 |
| EPS (Diluted) | $0.59 |
| Shares Outstanding (Basic) | 1.37B |
| Shares Outstanding (Diluted) | 1.38B |
Key Highlights
- 1Net sales for the third quarter of fiscal year 2017 increased by 5% year-over-year to $7.3 billion, driven by broad-based growth across segments and contributions from recent acquisitions.
- 2Net income attributable to Medtronic decreased by 25% to $821 million in the third quarter of fiscal year 2017, impacted by significant special charges and litigation expenses.
- 3Diluted earnings per share decreased to $0.59 for the third quarter of fiscal year 2017, down from $0.77 in the prior year's comparable quarter.
- 4The company generated $5.1 billion in cash flow from operating activities for the nine months ended January 27, 2017, and $4.2 billion in free cash flow for the same period.
- 5Medtronic continued to invest in growth through acquisitions, notably HeartWare International, Inc. and Smith & Nephew's gynecology business, which contributed to net sales.
- 6Restructuring charges of $21 million and $162 million were recorded for the three and nine months ended January 27, 2017, respectively, largely related to the integration of Covidien.
- 7The company maintained a strong liquidity position with $2.8 billion in cash and cash equivalents at the end of the quarter and an undrawn $3.5 billion revolving credit facility.